Nyxoah SA (XBRU:NYXH)
€ 8.1 0 (0%) Market Cap: 303.16 Mil Enterprise Value: 255.51 Mil PE Ratio: 0 PB Ratio: 2.66 GF Score: 47/100

Nyxoah SA at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 01:30PM GMT
Release Date Price: €6.9 (+2.68%)
Bill Plovanic
Canaccord Genuity Group Inc. - Analyst

Thank you for joining us at Canaccord's 43rd Annual Global Growth Conference. I'm Bill Plovanic, one of the Canaccord senior medical technology analysts. We're excited to host Nyxoah, and with us today from Nyxoah is Olivier Taelman, CEO, and Loïc Moreau, CFO. We're going to do a presentation, followed by a Q&A when we're -- after the presentation. And with that, I'll hand the podium over to Olivier.

Olivier Taelman
Nyxoah SA - CEO

Okay, thank you, and thank you for having us and inviting Nyxoah to the conference. The Nyxoah story is a story that is a story of neuromodulation in the field of obstructive sleep apnea. So I already can go to the first slide, and we like to call it Nyxoah's blueprint for success, or I'd like to refer to this as the trinity for success in medtech. In fact, there are three key pillars.

One is you need to have an existing and a large market. If we look at obstructive sleep apnea, I think it's obvious that the market is huge. We see, in the US alone, a $10 billion

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot